IOVA News and Press, Iovance Biotherapeutics Inc. From 02/28/23

Iovance Biotherapeutics press release ( NASDAQ: IOVA ): Q4 GAAP EPS of -$0.64 in-line. Iovance had $478.3 million in cash, cash equivalents, investments and restricted cash at December 31, 2022, compared to $602.1 million at December 31, 2021. Research...

SAN CARLOS, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor infiltrating lymphocyte, TIL, and peripheral-blood lymphocyte, PBL), today reported fourth quarter and...

Summary This is not an immediate call to start buying technology willy nilly. Or is this a tech only announcement. I'm merely projecting that selling pressure will likely reach a crescendo once the Fed raises rates again. Put together a shopping list. You have time to understand the...

SAN CARLOS, Calif., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report its fourth quarter and full year 2022 financial results on Tuesday, February 28, 2023. Managemen...

Summary Iovance Biotherapeutics, Inc. is poised to complete its rolling Biologic License Application for advanced melanoma this quarter. The recent Proleukin acquisition ensures a strong supply of IL2 for its Tumor Infiltrating Lymphocytes. Aside from gaining approval for melanoma, ...

Summary Iovance Biotherapeutics is a company that develops cancer immunotherapies, including lifileucel, an autologous cancer immunotherapy. Lifileucel is produced by collecting TILs from a patient's tumor and infusing them back into the patient and is a form of personalized medicine. ...

Iovance Biotherapeutics ( NASDAQ: IOVA ) added ~8% in the morning hours Friday as Piper Sandler upgraded the clinical-stage biotech to Overweight from Neutral, citing potential FDA approval for its lead asset lifileucel in melanoma later this year. The analyst Joseph Catanzaro exp...

Investors were more than cheered by a business update from cancer-focused biotech Iovance Biotherapeutics (NASDAQ: IOVA) on Monday. As a result, the company's stock shot well higher by nearly 12% on the day. That was impressive even by the bullish standards of the market on a day when the...

Iovance Biotherapeutics ( NASDAQ: IOVA ) is trading ~9% higher premarket after it acquired worldwide rights for Proleukin from Clinigen Limited for about £208.4M. Under the agreement, Iovance will pay an upfront payment of £166.7M, a £41.7M milestone p...

Acquisition of Worldwide Rights to Proleukin ® Provides Immediate and Ongoing Revenue and Secures IL-2 Supply for Clinical and Future Commercial TIL Therapy Positive FDA Feedback on Phase 3 Confirmatory Study in Frontline Advanced (Metastatic or Unresectable) Melanoma P...